EI
LPCN icon

EAM Investors’s Lipocine LPCN Stock Holding History

EAM Investors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-38,694
Closed -$901K – 303
2022
Q1 		$901K Buy
+38,694
New +$810K 0.17% 263
2016
Q2 		– Sell
-21,724
Closed -$3.75M – 334
2016
Q1 		$3.75M Sell
21,724
-1,927
-8% -$329K 0.59% 22
2015
Q4 		$5.2M Buy
23,651
+3,437
+17% +$721K 0.68% 10
2015
Q3 		$4.07M Buy
+20,214
New +$4.68M 0.64% 18

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

EAM Investors's LPCN Position: Q2 2022 in Review

EAM Investors sold out of Lipocine (LPCN) in Q2 2022, closing a stake of 38,694 shares — an estimated $901K sold.

EAM Investors first reported a position in LPCN in Q3 2015 and held it in 4 quarters. The position peaked at $5.2M in Q4 2015. 46 funds tracked by Wall St. Rank hold LPCN as of Q2 2022.

  • EAM Investors reported no remaining Lipocine position as of Q2 2022 after selling out during the quarter.
  • EAM Investors sold 38,694 Lipocine shares in Q2 2022, an estimated $901K.
  • EAM Investors first reported a position in Lipocine in Q3 2015 and held it in 4 quarters.
  • EAM Investors's Lipocine position peaked at $5.2M in Q4 2015.
  • 46 funds tracked by Wall St. Rank held Lipocine as of Q2 2022.

Based on EAM Investors's 13F filing for Q2 2022, filed 12 Aug 2022.